IBI3001

Innovent Biologics (Suzhou) Co. Ltd. · Phase 1 active Small molecule

At a glance

Generic name	IBI3001
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IBI3001 CI brief — competitive landscape report
IBI3001 updates RSS · CI watch RSS
Innovent Biologics (Suzhou) Co. Ltd. portfolio CI